Abstract

**Purpose:** Aggressive cutaneous squamous cell carcinoma (cSCC) is often a disfiguring and lethal disease. Very little is currently known about the mutations that drive aggressive cSCC.

**Experimental Design:** Whole-exome sequencing was performed on 39 cases of aggressive cSCC to identify driver genes and novel therapeutic targets. Significantly, mutated genes were identified with MutSig or complementary methods developed to specifically identify candidate tumor suppressors based upon their inactivating mutation bias.

**Results:** Despite the very high-mutational background caused by UV exposure, 23 candidate drivers were identified, including the well-known cancer-associated genes TP53, CDKN2A, NOTCH1, AJUBA, HRAS, CASP8, FAT1, and KMT2C (MLL3). Three novel candidate tumor suppressors with putative links to cancer or differentiation, NOTCH2, PARD3, and RASA1, were also identified as possible drivers in cSCC. KMT2C mutations were associated with poor outcome and increased bone invasion.

**Conclusions:** The mutational spectrum of cSCC is similar to that of head and neck squamous cell carcinoma and dominated by tumor-suppressor genes. These results improve the foundation for understanding this disease and should aid in identifying and treating aggressive cSCC.

Introduction

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer among Caucasians with an incidence of approximately one million cases per year (1). cSCC (25%) and basal cell carcinoma (BCC; 75%) are the major subtypes of nonmelanoma skin cancer (2). Most cSCC arise in the head and neck region because it is frequently exposed to sunlight and its ensuing UV radiation-induced DNA damage, which is the major etiologic factor (2). Immunosuppression, usually associated with organ transplantation, elevates the risk of developing cSCC by over 100-fold (3). Although cSCCs frequently respond well to conventional treatments, including electrodessication and curettage, cryosurgery, wide local excision, and radiotherapy, 3% to 5% of these tumors recur (4). According to a recent large study, patients with cSCC have a 3.7% risk of metastasis and 2.1% risk of disease-specific death (5). Clinically, aggressive cSCCs are characterized by frequent and multiple recurrences necessitating large surgical excisions, increased tendency for regional metastasis, and significant disease-related mortality (6). When aggressive or highly invasive cSCC occurs in the head and neck, surgical treatment can have profound functional, cosmetic, and psychosocial effects, sometimes leading to loss of an eye, ear, or a nose. This may require significant reconstruction and diminish quality of life.

In a large prospective study (6), a primary tumor size greater than or equal to 4 cm, the presence of perineural invasion (PNI), or invasion beyond the subcutaneous tissue were all associated with aggressive cSCC and...
The mutational spectrum of aggressive cutaneous squamous cell carcinoma contains a signature of exposure to UVB, which should aid in the definitive diagnosis for squamous tumors and metastases with ambiguous site of origin. In addition, the mutational landscape is dominated by tumor-suppressor genes, resembling that of head and neck squamous cell carcinoma, but includes novel candidate drivers. Many of the mutated genes are related to differentiation pathways. KMT2C mutations are associated with poor outcome and could represent a new biomarker for aggressive disease. They also suggest an epigenetic component to this disease that could possibly be targeted. Mutations in HRAS and STK19 are candidate oncogenic events, but are not yet targetable. These findings expand our knowledge of this disease and should aid in the development of genomically driven treatments.

Translational Relevance

The mutational spectrum of aggressive cutaneous squamous cell carcinoma contains a signature of exposure to UVB, which should aid in the definitive diagnosis for squamous tumors and metastases with ambiguous site of origin. In addition, the mutational landscape is dominated by tumor-suppressor genes, resembling that of head and neck squamous cell carcinoma, but includes novel candidate drivers. Many of the mutated genes are related to differentiation pathways. KMT2C mutations are associated with poor outcome and could represent a new biomarker for aggressive disease. They also suggest an epigenetic component to this disease that could possibly be targeted. Mutations in HRAS and STK19 are candidate oncogenic events, but are not yet targetable. These findings expand our knowledge of this disease and should aid in the development of genomically driven treatments.

Materials and Methods

Tissue processing

Fresh-frozen surgically resected tumor and patient-matched normal lymphocytes were obtained from consented patients treated for cSCC of the head and neck region at The University of Texas MD Anderson Cancer Center (Houston, TX), under an Institutional Review Board approved protocol. Frozen tissue was embedded in optimal cutting temperature (OCT) compound and completely sectioned. Tissue was washed once in PBS before isolating genomic DNA using an ArchivePure DNA purification kit (5Prime).

Library construction

Genomic DNA samples were constructed into Illumina paired-end precapture libraries according to the manufacturer’s protocol (Illumina Multiplexing Sample Prep Guide_1005361_D) with modifications as described in the BCM-HGSC Illumina Barcoded Paired-End Capture Library Preparation protocol that is accessible from the HGSC website (https://hgsc.bcm.edu/sites/default/files/documents/Illumina_Barcoded_Paired-End_Capture_Library_Preparation.pdf).

Illumina sequencing and copy number

Four precapture libraries were pooled together and hybridized in solution to the HGSC VCRome 2.1 design 1 (42 Mb; NimbleGen) according to the manufacturer’s protocol NimbleGen SeqCap EZ Exome Library SR User’s Guide (Version 2.2) with minor revisions. Exomes were sequenced on an Illumina HiSeq 2000 platform to an average coverage of \( \times 115 \). For both tumor and normal samples, >80% of bases achieved a q20 quality and \( \times 20 \) coverage. Details regarding library preparation and coverage for all samples are provided in the Supplementary Methods and Supplementary Table S4. Sequence analysis was performed using the HGSC Mercury analysis pipeline (https://www.hgsc.bcm.edu/software/mercury) to call mutations and generate BAM files (Supplementary Methods). Finalized BAM files generated from whole-exome sequencing were then used to generate copy-number data using an in house R package, BEDTools (16), and ABSOLUTE (17) to estimate the absolute copy number based on ploidy and purity (Supplementary Methods).

Significantly mutated genes

MutSigCV v1.4, which corrects for gene-specific background rates, was run on maf files that included flanking regions. IntOGen v2.3.0 software (Universitat Pompeu Fabra), which examines whether genes are enriched for potential impactful mutations beyond what is expected by chance (18), was run as an online package. Two additional algorithms were developed to recognize a bias toward inactivating mutations (see Supplementary Methods).

Statistical analyses

Wilcoxon rank sum tests and Fisher exact tests were used to test associations between individual mutation and
correlation coefficients and periorbital (including temple), cheek, or other. Pearson the remaining cases grouped as either preauricular, scalp, ear or lip were grouped into one high-risk site category, and respectively. For analysis of primary site, tumors from the continuous/ordinal variables and nominal variables, Kruskal–Wallis tests were used to test associations between total number of mutations and continuous/ordinal variables. Kappa coefficient correlations computed for each pair of genes and the results were summarized in a matrix plot. We used the Cox model score test to assess whether individual genes or total number of mutations are related with any of the time-to-event outcomes. All analyses were performed using SAS software (version 9.3; SAS Institute).

Results

Patient characteristics

To comprehensively characterize the somatic mutations in aggressive cSCC, we performed whole-exome sequencing on DNA from snap-frozen tumors and matched normal blood from 39 patients. These cases were considered aggressive because they presented with regional or distant metastasis or had at least one of the features associated with increased mortality previously described by Clayman and colleagues (Fig. 1; Supplementary Tables S1 and S2; ref. 6). All cSCCs studied arose on the head or neck, with the majority from the ear, preauricular, scalp, or periorbital regions: 38.5% were recurrent, 25.6% were persistent, and 35.9% were previously untreated. Seven of the samples were from metastatic sites. The majority of cSCCs (71.8%) had invaded beyond the subcutaneous space, 48.7% had PNI present, 43.6% were poorly differentiated, and 100% of evaluable cases had Clark levels ≥4.

Exome sequencing

Before sequencing, samples were evaluated by a trained pathologist and found to have an average tumor cellularity of 49.4% ± 22.4% as assessed visually (Supplementary Table S3). All specimens had greater than 10% tumor nuclei by pathology and sequencing analysis. Samples were sequenced to ×115 average coverage (Supplementary Table S4). A total of 108,034 somatic alterations were detected in 16,588 genes (Supplementary Table S5). The total number of mutations/patient ranged from 86 to 12,112. A median of 61.2 mutations/Mb was detected in this cohort (Fig. 2A). This mutation frequency is one of the highest mutation rates ever detected, is more than four times as high as the rate in melanoma (14), and is higher than the rate in other squamous tumor types (Fig. 2A). These tumors did not contain functionally relevant POLE mutations (19). In addition, the tumors were largely clonal. Less than 15% of mutated genes were found to have a low allele fraction (Supplementary Table S6), and only four samples had a subclonal genome fraction >15% (Supplementary Table S3). Although many of the tumors were previously treated there was no difference in the number (Supplementary Fig. S1A) or types (Supplementary Fig. S1B) of mutations between treated and untreated tumors. Instead, the vast majority of mutations appear to be caused by exposure to UV light, as is expected for skin tumors. UVB exposure is known to cause C>T transitions often following a pyrimidine base. When averaged across the cohort 73% of events were C>T transitions (Fig. 2B and C) and 87% of those were at a C following a pyrimidine base. In addition, 5.6% of events were dinucleotide polymorphisms (DNPs), which are another signature of UV exposure (Fig. 2B and C). A few select tumor types are shown for comparison (Fig. 2B).

Interestingly, four of the tumors did not appear to have a signature of UVB exposure (Fig. 2C). They had a much lower rate of C>T mutations (average 39% C>T) and a lower overall number of mutations (average 294). This mutation signature is more similar to that of human papilloma virus–negative head and neck squamous cell carcinoma (HNSCC), with a C>T frequency around 40% (Fig. 2B; ref. 20). These tumors represent all of the nose tumors in the cohort. Subsequent review of these clinical features that result in upstaging by AJCC criteria are shown in red.
histories was ambiguous to the source epithelium for the lesion, cutaneous, or mucosal. It is possible that these tumors arose from the mucosal surface of the nose but grew out to the skin surface.

Given the high background rate of mutations in cSCC it is difficult to identify candidate driver genes. Previous sequencing studies of cSCC did not include enough cases for statistical determination of drivers and relied on frequency of mutations alone. We performed MutSig analysis (21) and identified 11 genes with a q value of <0.1 (Table 1 and Supplementary Table S7); however, two of these (RBM46 and DCLK1) had low allelic fractions, suggesting that they may not be true drivers (Supplementary Table S6). Because of the high background rate, we undertook additional methods to identify candidate driver genes. Analysis using the Integrative Onco Genomics (IntOGen) package (18), which scores genes according to the cumulative predicted functional impact of missense and other nonsynonymous mutations, identified 292 candidate genes below the FDR cutoff of 0.1. Only seven of the genes detected as candidate drivers by IntOGen were also significant by MutSig. Because of the large number of significantly mutated genes detected by IntOGen (Supplementary Table S8), it is likely that many were false positives or passengers. We therefore sought out additional methods to identify drivers that would have increased specificity and not be affected greatly by a high-mutation background. Tumor-suppressor genes frequently have a high proportion of inactivating mutations, and this signature has been used by others to identify putative tumor suppressors that may be drivers from cancer-sequencing data (22). We developed two algorithms to detect a bias toward inactivating mutations.

Figure 2. Mutation frequency and types in cSCC. A, mutation frequency in cSCC compared with other tumor types. Median value is shown and indicated by the horizontal line. Non-cSCC samples are TCGA data from Lawrence et al. (24). B, mutation types in cSCC compared with other tumor types. Mutation type frequencies were calculated for each sample and then averaged across the cohort to eliminate bias from highly mutated samples. HNSCC and LUSC are TCGA data from Kandoth et al. (20) Melanoma data are from Hodis et al. (14). C, mutation types by patient.
Although the candidate tumor-suppressor genes (Supplementary Table S9), including five well-known tumor suppressors that were identified as significant by all four methods, whereas SNX25, EIF2D, and PARD3 were significant by the three alternative methods but not by

<table>
<thead>
<tr>
<th>Genes</th>
<th>MutSig q value</th>
<th>IntOGen FM q value</th>
<th>$\chi^2$ FDR</th>
<th>Multinomial FDR</th>
<th>Patients (number) TCGA HNSC HPV (243)</th>
<th>Patients (number) TCGA LSACC (178)</th>
<th>Patients (number) TCGA SKCM (278)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP53</td>
<td>0.000</td>
<td>0.000</td>
<td>&lt;1.00E−05</td>
<td>37 (94.9%)</td>
<td>203 (83.5%)</td>
<td>161 (90.4%)</td>
<td>46 (16.5%)</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>9.34E−07</td>
<td>3.48E−13</td>
<td>2.81E−12</td>
<td>17 (43.6%)</td>
<td>63 (25.9%)</td>
<td>32 (18.0%)</td>
<td>42 (15.1%)</td>
</tr>
<tr>
<td>PEG10</td>
<td>3.66E−06</td>
<td>ND</td>
<td>9.69E−01</td>
<td>9 (23.1%)</td>
<td>2 (0.8%)</td>
<td>3 (1.7%)</td>
<td>5 (1.8%)</td>
</tr>
<tr>
<td>NOTCH2</td>
<td>1.85E−03</td>
<td>2.79E−07</td>
<td>4.20E−08</td>
<td>20 (51.3%)</td>
<td>12 (4.9%)</td>
<td>13 (7.3%)</td>
<td>22 (7.9%)</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>2.10E−02</td>
<td>0.000</td>
<td>1.04E−05</td>
<td>23 (59.0%)</td>
<td>49 (20.2%)</td>
<td>15 (8.4%)</td>
<td>9 (3.2%)</td>
</tr>
<tr>
<td>HRAS</td>
<td>2.10E−02</td>
<td>2.55E−02</td>
<td>9.69E−01</td>
<td>8 (20.5%)</td>
<td>11 (4.5%)</td>
<td>5 (2.8%)</td>
<td>3 (1.1%)</td>
</tr>
<tr>
<td>BBS9</td>
<td>2.10E−02</td>
<td>6.61E−01</td>
<td>3.22E−01</td>
<td>9 (23.1%)</td>
<td>5 (2.1%)</td>
<td>7 (3.9%)</td>
<td>10 (3.6%)</td>
</tr>
<tr>
<td>CASP8</td>
<td>2.93E−02</td>
<td>1.47E−02</td>
<td>2.96E−01</td>
<td>9 (23.1%)</td>
<td>24 (9.9%)</td>
<td>2 (1.1%)</td>
<td>9 (3.2%)</td>
</tr>
<tr>
<td>DCLK1</td>
<td>3.99E−02</td>
<td>ND</td>
<td>8.96E−01</td>
<td>17 (43.6%)</td>
<td>3 (1.2%)</td>
<td>4 (2.2%)</td>
<td>10 (3.6%)</td>
</tr>
<tr>
<td>RBM46</td>
<td>3.67E−02</td>
<td>ND</td>
<td>1.03E−01</td>
<td>13 (33.3%)</td>
<td>0 (0.0%)</td>
<td>1 (0.6%)</td>
<td>15 (5.4%)</td>
</tr>
<tr>
<td>AJUBA</td>
<td>9.99E−02</td>
<td>7.40E−12</td>
<td>8.28E−03</td>
<td>7 (17.9%)</td>
<td>17 (7.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>SNX25</td>
<td>1 2.12E−02</td>
<td>3.95E−05</td>
<td>1.66E−02</td>
<td>7 (17.9%)</td>
<td>4 (1.6%)</td>
<td>3 (1.7%)</td>
<td>2 (0.7%)</td>
</tr>
<tr>
<td>EIF2D</td>
<td>1 5.43E−02</td>
<td>3.35E−05</td>
<td>8.81E−02</td>
<td>2 (6.1%)</td>
<td>0 (0.0%)</td>
<td>1 (0.6%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>PARD3</td>
<td>1 6.04E−02</td>
<td>1.03E−02</td>
<td>4.00E−04</td>
<td>12 (30.8%)</td>
<td>2 (0.8%)</td>
<td>2 (0.8%)</td>
<td>6 (2.2%)</td>
</tr>
<tr>
<td>OPN3</td>
<td>1 1.28E−02</td>
<td>2.26E−03</td>
<td>3.80E−01</td>
<td>4 (10.3%)</td>
<td>0 (0.0%)</td>
<td>2 (1.1%)</td>
<td>4 (1.4%)</td>
</tr>
<tr>
<td>FBXO21</td>
<td>1 2.13E−02</td>
<td>2.44E−02</td>
<td>1.22E−01</td>
<td>5 (12.8%)</td>
<td>2 (0.8%)</td>
<td>2 (1.1%)</td>
<td>6 (2.2%)</td>
</tr>
<tr>
<td>DCLRE1A</td>
<td>4.49E−02</td>
<td>2.44E−02</td>
<td>1.61E−01</td>
<td>5 (12.8%)</td>
<td>2 (0.8%)</td>
<td>1 (0.6%)</td>
<td>6 (2.2%)</td>
</tr>
<tr>
<td>COBLL1</td>
<td>1 5.43E−02</td>
<td>3.22E−01</td>
<td>6.90E−02</td>
<td>9 (23.1%)</td>
<td>3 (1.2%)</td>
<td>5 (2.8%)</td>
<td>18 (6.5%)</td>
</tr>
<tr>
<td>RASA1</td>
<td>1 1.21E−01</td>
<td>8.93E−05</td>
<td>4.19E−03</td>
<td>5 (12.8%)</td>
<td>13 (5.3%)</td>
<td>10 (5.6%)</td>
<td>3 (1.1%)</td>
</tr>
<tr>
<td>SEC31A</td>
<td>1 2.14E−02</td>
<td>6.82E−02</td>
<td>8.00E−02</td>
<td>7 (17.9%)</td>
<td>4 (1.6%)</td>
<td>5 (2.8%)</td>
<td>6 (2.2%)</td>
</tr>
<tr>
<td>ZNF644</td>
<td>1 2.42E−01</td>
<td>3.95E−05</td>
<td>8.72E−02</td>
<td>6 (15.4%)</td>
<td>3 (1.2%)</td>
<td>3 (1.7%)</td>
<td>5 (1.8%)</td>
</tr>
<tr>
<td>KMT2C</td>
<td>1 3.20E−01</td>
<td>1.14E−03</td>
<td>9.29E−03</td>
<td>15 (38.5%)</td>
<td>21 (6.6%)</td>
<td>29 (16.3%)</td>
<td>45 (16.2%)</td>
</tr>
<tr>
<td>FAT1</td>
<td>1 ND</td>
<td>4.29E−10</td>
<td>1.00E−05</td>
<td>17 (43.6%)</td>
<td>64 (26.3%)</td>
<td>26 (14.6%)</td>
<td>27 (9.7%)</td>
</tr>
<tr>
<td>KMT2D</td>
<td>1 7.80E−01</td>
<td>1.20E−01</td>
<td>1.50E−02</td>
<td>27 (69.2%)</td>
<td>43 (17.7%)</td>
<td>36 (20.2%)</td>
<td>62 (22.3%)</td>
</tr>
<tr>
<td>NFE2L2</td>
<td>1 ND</td>
<td>ND</td>
<td>ND</td>
<td>0 (0.0%)</td>
<td>17 (7.0%)</td>
<td>27 (15.2%)</td>
<td>3 (1.1%)</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>1 4.09E−01</td>
<td>3.22E−01</td>
<td>4.03E−01</td>
<td>4 (10.3%)</td>
<td>45 (18.5%)</td>
<td>28 (15.7%)</td>
<td>10 (3.6%)</td>
</tr>
<tr>
<td>RAC1</td>
<td>1 9.43E−01</td>
<td>6.95E−01</td>
<td>ND</td>
<td>2 (6.1%)</td>
<td>8 (3.3%)</td>
<td>2 (1.1%)</td>
<td>20 (7.2%)</td>
</tr>
<tr>
<td>BRAF</td>
<td>1 9.69E−01</td>
<td>1</td>
<td>7 (17.9%)</td>
<td>3 (1.2%)</td>
<td>8 (4.5%)</td>
<td>140 (50.4%)</td>
<td>140 (50.4%)</td>
</tr>
<tr>
<td>NRAS</td>
<td>1 6.95E−01</td>
<td>ND</td>
<td>2 (6.1%)</td>
<td>1 (0.4%)</td>
<td>0 (0.0%)</td>
<td>86 (30.9%)</td>
<td>86 (30.9%)</td>
</tr>
<tr>
<td>STK19</td>
<td>1 4.02E−01</td>
<td>9.69E−01</td>
<td>1</td>
<td>8 (20.5%)</td>
<td>3 (1.2%)</td>
<td>4 (2.2%)</td>
<td>4 (1.4%)</td>
</tr>
</tbody>
</table>

NOTE: TCGA data were collected from cBioPortal. TCGA significance was determined by MutSig in the pan-cancer analysis of Lawrence et al. (24). Abbreviation: ND, not determined.

*aStatistically significant genes.
MutSig. Furthermore, the known tumor-suppressor genes FAT1 and KMT2C (MLL3) and a putative tumor-suppressor RASA1 (22, 23) were significant by the two methods detecting inactivation bias. The distribution for these mutations among the cohort can be seen in Fig. 3 along with the frequency of inactivating, missense, and silent mutations.

Interestingly, eight of the top 23 genes were also found to be significantly mutated in HNSCC (Table 1; ref. 24). Only four genes were significant in lung squamous cell carcinoma (LUSC) and two genes were significant in melanoma (SKCM; ref. 24). The genes common to cSCC and HNSCC are TP53, CDKN2A, NOTCH1, HRAS, CASP8, AJUBA, RASA1, FAT1, and KMT2D. The presence of moderately frequent mutations in eight common genes suggests that the biology of cSCC may be similar to that of HNSCC.

In both cSCC and HNSCC, NOTCH1 alterations appear to be inactivating (Fig. 4) because the missense mutations cluster in the EGF-like repeats responsible for ligand binding, and the truncating mutations are distributed throughout the gene but not clustered in the C-terminal PEST domain, in contrast with what is found for T-cell acute lymphoblastic leukemia (ALL). NOTCH1 and NOTCH2 were similarly mutated in >50% of cSCC cases and more than 30% of the mutations are inactivating. We recently showed that NOTCH1 is a tumor-suppressor gene in HNSCC (25) but the role of NOTCH2 in cancer is poorly understood. NOTCH2 mutations are not statistically significant in HNSCC by MutSig, but do have a high inactivating mutation ratio in this cancer as well (Fig. 4).

We next compared a few genes significantly mutated in related tumor types but not in cSCC. Mutations in the oxidative stress gene NFE2L2 were first described in LUSC (15% of cases; ref. 26) and later found in HNSCC (7%; ref. 24). No mutations in NFE2L2 were found in this cSCC cohort. PIK3CA is also significantly mutated in LUSC (16%) and HNSCC (19%), but was mutated only five times in 4 cSCC patients (10%) and was not statistically significant (Table 1). In addition, the mutations included two inactivating mutations and no mutations in the classical hotspots (E545 and H1047; Supplementary Table S5).

Melanoma is characterized by frequent hotspot mutations in BRAF and NRAS (14). No hotspot mutations in BRAF or NRAS were observed in cSCC. However, hotspot mutations in RAC1 and STK19 have been reported in melanoma and were found in this cohort. We observed one P29S mutation in RAC1, and five mutations around D89 in STK19. These included three D89N, one E88K, and one P90S mutations (Supplementary Table S5).

We also identified two new candidate tumor-suppressor genes for cSCC. PARD3 and RASA1 were mutated in 31% and 13% of patients with cSCC (Table 1), with 33% and 66% of their mutations predicted to truncate or eliminate the proteins (Fig. 3), respectively. RASA1 was identified in pan-cancer analyses and HNSCC as a candidate tumor-suppressor gene because of its high inactivation mutation ratio (22, 24).

Kappa analysis was performed to identify correlations between the mutations in each gene (Supplementary Table S11). HRAS was highly correlated with AJUBA (0.423, $P = 0.008$) and inversely associated with TP53.
TP53 and HRAS are also inversely correlated in HNSCC.

Because four tumors lacked a UV signature, we repeated the MutSig analysis while excluding those tumors. The top 12 most significant genes remained at the top of the list; however, one new gene was added as the 10th most significant gene, RIPK4 ($q = 0.053$). This gene is quite interesting because it encodes a serine/threonine kinase essential for keratinocyte differentiation (27). RIPK4 was mutated in 28% of the tumors with a UV signature, with all mutations clustering in either exon 2 or exon 8, which encode the kinase and ankyrin repeat domains, respectively. There was also a high ratio of nonsense, frameshift, and splice mutations (35%) that was nearly significant by the two methods detecting inactivation bias, suggesting selection for inactivation of the gene in cSCC.

---

**Figure 4.** Mutations in NOTCH1 and NOTCH2 appear to be inactivating in cSCC. A, the spectrum and location of NOTCH1 mutations observed in cSCC, HNSCC (TCGA data), are compared with T-cell ALL (COSMIC data) in which NOTCH1 alterations are instead activating. In both cSCC and HNSCC, most missense mutations cluster in the N-terminal EGF-like repeats in which ligand binding occurs, and truncating mutations are distributed throughout the gene, whereas, in leukemia truncating mutations are confined to the C-terminal PEST domain responsible for degradation of activated intracellular NOTCH1 and missense mutations cluster in the heterodimerization domain where they cause ligand-independent activation. B, NOTCH2 alterations in cSCC and HNSCC have a similar pattern because missense mutations are clustered in the EGF-like domains and truncating mutations are scattered throughout the gene, suggesting the alterations inactivate function. Red dots, truncating mutations (splice, frameshift, or nonsense); green dots, missense mutations; black dots, inframe insertions or deletions; and purple dots, residues affected by different mutation types. NOTCH domains are indicated with different colors. Light green, EGF-like repeat; dark green, calcium-binding EGF domain; yellow, LNR (negative regulatory) repeat; blue, heterodimerization domain (HD); orange, transmembrane (TM) region; pink, RAM domain; purple, ankyrin repeats; blue, transactivation domain (TAD); and red, proline glutamic acid serine-threonine rich (PEST) domain.

(-0.107, $P = 0.004$). TP53 and HRAS are also inversely correlated in HNSCC.
Copy-number alterations

Copy-number values were calculated from the exome-sequencing coverage data and adjusted for purity and ploidy by using the ABsolute algorithm. Large regions of copy-number gain were frequently detected (in >25% of samples) on chromosomes 7, 8q, 9q, 14, and 20, and regions of loss were detected on 3p, 4, 5q, 8p, 9p, 11, 17p, 18, 19, and 21 (Supplementary Fig. S2 and Supplementary Table S12). The CCND1 region of chromosome 11q was also focally amplified. In the copy-number data, as with the mutation data, there are many similarities between cSCC and HNSCC. For example, both tumor types have losses in 3p, 5q, 8p, 18, and 21 and gains in 3q, 5p, 8q, 14, and 20 (25).

Clinical significance

To begin addressing the importance of genetic alterations in cSCC, the top candidate genes along with the total number of mutations per patient were analyzed for clinical-pathologic associations. This analysis correlated 29 different clinical ordinal characteristics, three continuous clinical variables, and eight different measurable parameters related to time intervals or patient status (Supplementary Table S2). Although all of the patients in this cohort were selected based upon a clinical diagnosis of cSCC, to maintain clinical uniformity the four nasal cases with ambiguous site of origin were removed from the clinical analyses. As these studies were exploratory in nature, multiple testing corrections were not applied so that sensitivity could be maximized. A summary matrix of all \( P \) values obtained for the clinical parameters tested by gene appears in Supplementary Table S13. The total number of mutations observed per tumor did not correlate with any of the genes or clinical-pathologic parameters examined except for histologic subtype (\( P = 0.02 \)). Tumors classified as acantholytic had a median number of mutations (3589) that was roughly 1.5 times greater than tumors with no specific histologic subtype (2295) and more than triple the median number of mutations (1,033) in tumors with sarcomatoid or adenosquamous histology.

Tumors with AJUBA mutations were positively correlated with depth of invasion (\( P = 0.02 \)), and on average invaded with a depth (16.0 ± 6.4 mm) almost twice that of tumors lacking the mutation (8.4 ± 5.6 mm). The presence of PNI, a known aggressive feature, was positively associated with...
mutations in NOTCH2 ($P = 0.04$; Fig. 5A). Approximately 70% of patients with NOTCH2 mutations had PNI present compared with just 33% of patients with no NOTCH2 mutation. Interestingly, NOTCH2 mutations were also associated with primary tumor site ($P = 0.04$), as the presence of NOTCH2 mutation was more common in cSCCs arising in the scalp or periorbital regions compared with the ear (Fig. 5A). The increased tendency for tumors with NOTCH2 mutations to have PNI may be independent from tumor site, as there was no significant association between tumor site and PNI ($P = 0.19$).

There was a highly significant positive association between bone invasion and KMT2C mutations ($P = 0.008$). Only 10% of patients with wild-type KMT2C had bone invasion, compared with 53% of patients with KMT2C mutation (Fig. 5A). Consistent with the positive association between KMT2C and bone invasion, patients with KMT2C mutation had significantly shorter recurrent-free survival times ($P = 0.003$) with a median recurrent survival of 21.6 months compared with 167.5 months for patients with wild-type KMT2C (Fig. 5B). The HR for recurrence or death for patients with KMT2C mutation was 5.16 (95% confidence interval, 1.55–17.18) compared with those whose tumors were wild-type. Similarly, patients with tumors harboring KMT2C mutation had trends toward shorter time to disease recurrence ($P = 0.07$), and shorter overall survival (OS; $P = 0.09$). Poor prognosis of patients with KMT2C mutation appeared to be independent from bone invasion, as patients with bone invasion did not have shortened recurrent-free survival times ($P = 0.98$).

Discussion

We have generated the first list of significantly mutated candidate driver genes in aggressive cSCC. The background mutation rate in cSCC is so high that more than half of all genes were mutated and 218 genes were mutated in at least half of the patients in this study. We report what are likely to be many of the most important drivers in aggressive cSCC. Currently, very few studies have comprehensively examined the mutational landscape of cSCC. These prior studies were unable to achieve statistical significance and little clinical information exists about their cohorts. Thus, it is presently unknown whether the candidate drivers we identified are enriched in aggressive cSCC compared with cSCC with a more benign clinical course.

Six of the top genes in aggressive cSCC, TP53, CDKN2A, NOTCH1, NOTCH2, HRAS, and FAT1 were previously reported by South and colleagues (12) in a cohort comprised of 20 cSCCs derived mostly from patients with immunosuppression secondary to organ transplantation. It is interesting to note that cSCCs that arise in organ transplant recipients are frequently aggressive, suggesting a common biology despite differences in predisposing risk factors. Interestingly, another group has recently characterized the genomic landscape of BCC (15), and also observed frequent mutations in NOTCH1, NOTCH2, and TP53. However, PTCH1 was the only gene in BCC found to be significantly mutated. PTCH1 mutations occurred in 75% of BCC tumors and 70% of the alterations were inactivating. In this cSCC cohort, PTCH1 mutations occurred in just 17% of patients and only two mutations were inactivating, suggesting that PTCH1 is not a driver in aggressive cSCC.

The mutational spectrum of cSCC is quite similar to that of HNSCC. Eight of the top mutated genes are shared between these tumor types, both derived from stratified squamous epithelia. The major mutational difference between cSCC and HNSCC is the UV signature. We identified four tumors from the nose that lacked the UV signature. Subsequent review of those patient records identified ambiguity in the source of the tumor with respect to the skin or mucosa of the nose. Some mucosal tumors in the nose can grow through the skin and present as an apparently cutaneous lesion, especially for large tumors. Similarly, nodal or parotid metastases in the head and neck region may have uncertainty regarding whether the tumor originated in skin or mucosa. These data suggest that the UV signature may be able to aid clinicians in making a definitive diagnosis in these cases.

Although high frequencies of both NOTCH1 and NOTCH2 mutations in cSCC were previously reported by two groups (11, 12), we were able to show for the first time that both genes are significantly mutated in cSCC by using MutSig. Recently, we demonstrated that NOTCH1 behaves functionally as an in vitro and in vivo tumor suppressor in HNSCC (25). A similar role is likely in cSCC, because conditional knockout of NOTCH1 in mouse skin predisposes animals to skin tumors (28). A role for NOTCH2 in cancers is less clear because mice with conditional knockout of NOTCH2 are not predisposed to tumors (29). However, activated NOTCH2 can arrest the growth of keratinocytes (29) in vitro and combined inactivation of both NOTCH1 and NOTCH2 can more severely alter differentiation of skin than loss of NOTCH1 alone (29). Collectively, the data suggest NOTCH2 activation may inhibit tumor growth and future functional studies are needed.

It is possible that the cell of origin for the tumor may influence the relative roles of NOTCH1 and NOTCH2. NOTCH1 and its presumed ligand JAG1 are expressed in the lower to middle epidermal layers, whereas expression of NOTCH2 and its presumed ligands, JAG2 and DLL1, are confined to the basal cells of skin (29). NOTCH1 and NOTCH2 may both be a barrier to carcinogenesis in some systems (human), whereas NOTCH1 may be the primary barrier for other systems (mouse).

An interesting and novel candidate driver gene we identified was RIPK4, which is known to control keratinocyte differentiation (27). Inactivating mutations in this gene are associated with a severe autosomal recessive lethal disease in humans (30) known as Popliteal Pterygium Syndrome (also Bartsocas-Papas syndrome) that affects the face, limbs, and genitalia. Knockout of RIPK4 in mice produces a similar neonatal lethal syndrome accompanied by defective epidermal differentiation, including keratinocyte hyperplasia with expanded spinous and granular layers (27). The
clustering of RIPK4 mutations within the kinase and ankyrin repeat domains, strongly suggests that the mutations were nonrandom and support a hypothesis that RIPK4 is a putative tumor suppressor for aggressive cSCC.

Many of the identified genes are related to differentiation signaling. These include NOTCH1, NOTCH2, FAT1, AIU3A, CASP8, and RIPK4. Several of these genes were also identified in HNSCC and linked to differentiation there as well. This suggests a common and important barrier to tumorigenesis in these squamous epithelial tumors.

Another interesting candidate tumor-suppressor gene in cSCC is RASA1. RASA1 belongs to a family of RAS GTPase activating proteins, many of which have been implicated as tumor suppressors in cancer because they function to negatively regulate prooncogenic RAS (23). RAS GTPase family members with confirmed tumor-suppressor function include NF1, DAB2IP, and RASA12, which are frequently inactivated in tumors through genomic loss, mutation, or epigenetic silencing (23). Inactivation of these genes has been proposed to explain activation of the RAS pathway in tumors that do not harboring specific RAS mutations. The role of RASA1 in cancer has not been clearly defined, despite the fact that it is frequently inactivated by mutation in many other tumor types (22).

A primary goal of this study was to identify new targetable genes for the treatment of cSCC, because there are very few nonsurgical options for patients with aggressive disease. Unfortunately, we did not identify any easily targetable events. The most frequently altered genes are nearly all tumor-suppressor genes, similar to what was found in HNSCC (25). The most obvious oncogene identified is HHRAS, which has proven difficult to target. An interesting novel target is STK19. The pattern of mutational clustering suggests that they may activate the kinase. Although little is currently known about the function of STK19 and which drugs can target it, it is hoped that this genetic characterization of cSCC will lead to identification of driver pathways that will be targetable. Even if mutated tumor-suppressor genes are not directly targetable, it is possible that the pathways they define can be targetable through other codependent genes or that a synthetic lethality can be identified.

In this cohort of aggressive cSCC, we found frequent inactivating mutations in KMT2C, which encodes a component of a histone methylation complex involved in transcriptional regulation. Inactivating KMT2C mutations have been reported for a number of tumors, including cancers of the stomach (31), bladder (32), and breast (33). In the TCGA stomach cancer dataset there is a trend toward reduced OS in patients with KMT2C mutation compared with patients who are wild-type (median 13 vs. 59 months). In this aggressive cSCC cohort, patients with KMT2C mutations had significantly shorter recurrent-free survival, shorter time to recurrence, and were more likely to have bone invasion. The data support a role for KMT2C in the aggressive behavior of cSCC.

One of the challenges both patients and clinicians face with aggressive head and neck cSCC is the invasive tumor behavior and the innumerable recurrences that eventually require extensive surgeries; often affecting function and form. Therefore, the stakes are high in identifying the subset of cSCC that will manifest an unfavorable biology. Understanding the genomic signatures of aggressive cSCC provides an opportunity to intensify upfront therapies to prevent the morbid consequences of treating advanced disease. These results set the stage for understanding and recognizing the key drivers in this disease. The goal is to use this information to explore potential biomarkers that predict aggressive cSCC and identify genomically targeted therapies that are effective for those patients.

Disclosure of Potential Conflicts of Interest
R.A. Gibbs is a consultant/advisory board member for GE Clarent. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: C.R. Pickering, J.J. Lee, J.N. Myers, D.A. Wheeler, M.J. Frederick
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.R. Pickering, J.J. Lee, R.E. Saade, K.Y. Tsai, J.L. Currty, M.T. Tetzlaff, D.M. Muszy, H. Duddapaneni, R.A. Gibbs, M.J. Frederick
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.H. Zhou, J.A. Drummond, R.E. Saade, M.J. Frederick
Study supervision: R.A. Gibbs, J.N. Myers, D.A. Wheeler, M.J. Frederick
Other (collected the patient’s clinical, pathologic, and demographic data; reviewed all the pathologic slides; acquisition of the samples; made and reviewed all the frozen section slides of the samples for quality control; isolated the DNA from the samples for the sequencing): J.H. Zhou
Other (provide specimens for analysis): A.K. El-Naggar

Acknowledgments
The authors thank the patients for their courage and generosity. The authors thank the members of the Myers laboratory for moral support, technical support, and helpful discussions.

Grant Support
This work was supported by the Cancer Prevention Research Institute of Texas grant RP100233; NIH/National Institute of Dental and Craniofacial Research grant RC2DE020958; NIH Specialized Program of Research Excellence grants P50CA097007; Cancer Center Support Grant P30CA016672, and the Pantheon Program. M.J. Frederick is supported in part as a fellow of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. J.H. Zhou is supported by NIH grant T32CA163185.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 9, 2014; revised September 30, 2014; accepted October 1, 2014; published OnlineFirst October 10, 2014.
References


Clinical Cancer Research

Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1768

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/10/11/1078-0432.CCR-14-1768.DC1

Cited articles
This article cites 32 articles, 5 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/24/6582.full#ref-list-1

Citing articles
This article has been cited by 11 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/24/6582.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.